On February 24, 2025 Swarm Oncology Ltd. (‘Swarm Oncology’ or ‘Swarm’), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, reported a strategic partnership with Cellex Cell Professionals GmbH (‘Cellex’), a leading contract development and manufacturing organization (‘CDMO’) specializing in cell and gene therapy (‘CGT’) manufacturing with a particular focus on clinical and commercial supply of T cell therapies (Press release, Swarm Oncology, FEB 24, 2025, View Source [SID1234650489]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Despite advancements in oncology, more than 82% of patients with advanced metastatic cancer ultimately succumb to their disease. Current immunotherapies provide only limited survival benefits due to challenges such as T cell exhaustion, inadequate cell numbers, and limited antigen diversity. Swarm’s breakthrough T cell therapy platform, Swarm-T, integrates in vivo immune priming with proprietary ex vivo manufacturing to generate highly potent, non-exhausted, polyclonal T cells. Unlike conventional approaches, Swarm-T overcomes key limitations by delivering a powerful and sustained immune attack against solid tumors.
Through this partnership, Cellex will supply cellular starting material and oversee process transfer, GMP manufacturing, and quality control. Additionally, Cellex will provide regulatory compliance support and specialized infrastructure to accelerate Swarm’s therapies toward clinical trials in 2026. The partnership aims to accelerate clinical timelines, reduce manufacturing bottlenecks, and enhance scalability, to bring Swarm’s innovative T cell therapies to solid tumor patients in need.
Martin Olin, CEO of Swarm, said: "Swarm’s mission is to transform immunotherapy by overcoming its limitations and driving solid cancers into long-term remission. With Cellex’s deep expertise in cell collection, therapy manufacturing, and regulatory compliance, we can ensure a seamless, high-quality manufacturing process and advance clinical development, bringing life-changing treatments to patients with the reliability and scale they need."
"We are excited to contribute to Swarm’s mission to drive innovation in solid cancer treatment," said Prof. Dr. Gerhard Ehninger, Cellex’s CEO. "With our modern facilities and over 10 years of experience in T cell therapy manufacturing, we are well-positioned to help bring these transformative therapies to the clinic faster and more efficiently."